Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists

Two types of immune checkpoint inhibitors, both antibodies that target cytotoxic T‐lymphocyte antigen‐4 and those that target programmed cell death‐protein 1, have been approved for use in melanoma, non‐small‐cell lung cancer, and renal cell carcinoma as first‐line or second‐line therapy. Their adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Illouz, Frédéric, Briet, Claire, Cloix, Lucie, Le Corre, Yannick, Baize, Nathalie, Urban, Thierry, Martin, Ludovic, Rodien, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548876/
https://www.ncbi.nlm.nih.gov/pubmed/28719055
http://dx.doi.org/10.1002/cam4.1145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548876/
https://www.ncbi.nlm.nih.gov/pubmed/28719055
http://dx.doi.org/10.1002/cam4.1145

Ejemplares similares